<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548518</url>
  </required_header>
  <id_info>
    <org_study_id>Tri Fluvac Vaccine in Elderly</org_study_id>
    <nct_id>NCT04548518</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly</brief_title>
  <official_title>A Phase III Double Blinded, Randomized, Controlled, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Subjects Aged 65 Years and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Government Pharmaceutical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aim to evaluate the Immunogenicity with two groups of participants who will&#xD;
      received a seasonal trivalent split, inactivated influenza vaccine (A/H1N1; A/H3N2 and B) or&#xD;
      an active comparator (licensed influenza vaccine).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III, non-inferiority double-blinded, randomized, controlled trial of&#xD;
      immunogenicity with two groups of participants who will received a seasonal trivalent split,&#xD;
      inactivated influenza vaccine (A/H1N1; A/H3N2 and B) or an active comparator (licensed&#xD;
      influenza vaccine).&#xD;
&#xD;
      A total of about 816 healthy Thai male and female adult volunteers ≥ 65 years of age; 408&#xD;
      participants will be randomized to receive the GPO Tri Fluvac and 408 will receive an active&#xD;
      comparator (a 1:1 ratio).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>non-inferiority double-blinded, randomized, controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percentage of seroconverted participants at 28 days post vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>seroconversion is defined as a serum HI antibody titer meeting the following four fold rising criteria:&#xD;
Pre-vaccination titer &lt;1:10 and a post-vaccination measured on Day 28 of ≥1:40; or&#xD;
Pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination measured on Day 28.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of serum HI antibodies at baseline (Day 0) and post- vaccination (Day 28).</measure>
    <time_frame>28 days</time_frame>
    <description>Geometric mean titers (GMTs) of serum HI antibodies pre- (Day 0) and post-vaccination (Day 28) for each of the three vaccine antigens. GMTs will be calculated with 95% CI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of participants with solicited local and systemic adverse events. post vaccination</measure>
    <time_frame>30 minutes, Day 1-3 post-vaccination</time_frame>
    <description>Solicited local adverse events including redness/erythema, swelling/induration, pain, and limitation of arm movement. Solicited systemic adverse events including fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, and headache.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of participants with unsolicited adverse event.</measure>
    <time_frame>180 days</time_frame>
    <description>Number and percentage of participants with unsolicited adverse event occuring during the entire study period (Days 0-180)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of participants with serious adverse event.</measure>
    <time_frame>180 days</time_frame>
    <description>Number and percentage of participants with serious adverse event occuring during the entire study period (Days 0-180)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of participants with HI response with and without pre-existing HI antibody.</measure>
    <time_frame>28 days</time_frame>
    <description>Number and percentage of participants with a HI antibody titer ≥1:40 (seroprotective level) to each of the three vaccine antigens.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">816</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GPO Tri Fluvac vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>408 participants will receive a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1)pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) produced by the Government Pharmaceutical Organization (GPO), Thailand. The vaccine to be administered by intramuscular (IM) injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Licensed Influenza vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>408 will receive a Licensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020 (consisting of A/Brisbane/02/2018 (H1N1) pdm-09-like virus, A/South Australia/34/2019 (H3N2)-like virus, and B/Washington/02/2019-like (B/Victoria lineage) virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GPO Tri Fluvac vaccine</intervention_name>
    <description>Each dose of Tri Fluvac contains a total of 45 micrograms (μg) hemagglutinin (HA) per 0.5 ml dose (15 μg HA per strain per dose), to be administered by intramuscular (IM) injection. Tri Fluvac is manufactured and formulated into a multiple-dose vial vaccine (2 doses) using thimerosal at relatively low concentration as preservative (≤ 5.75 μg mercury/ dose). Each 0.5 ml dose of vaccine may contain residual amounts of ovalbumin (≤ 1.0μg), formaldehyde (≤ 100μg), tween 80 (≤ 0.9μg), triton x-100 (≤0.05μg) and gentamicin (≤0.075μg).</description>
    <arm_group_label>GPO Tri Fluvac vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed influenza vaccine</intervention_name>
    <description>The comparator licensed influenza vaccine is a seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2020</description>
    <arm_group_label>Licensed Influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 65 years old on the day of screening, having Thai ID card or equivalent&#xD;
&#xD;
          -  Able to read and write in Thai and sign written informed consent form&#xD;
&#xD;
          -  Able to attend all scheduled visits and to comply with all trial procedures.&#xD;
&#xD;
          -  Healthy or medically stable, as established by medical history and physical&#xD;
             examination. For individuals with medical conditions, symptoms/signs, if present must&#xD;
             be stable, under control or unchanged for the past three months. If medication is used&#xD;
             to treat the condition, the medication dose must have been stable for at least one&#xD;
             month preceding vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another clinical trial involving any therapy within the previous&#xD;
             three months or planned enrollment in such a trial during the period of this study.&#xD;
&#xD;
          -  Hypersensitivity after previous administration of any vaccine.&#xD;
&#xD;
          -  Having a history of H1N1, H3N2 or FluB infection within 3 months preceding enrollment&#xD;
             to the trial&#xD;
&#xD;
          -  Vaccination against influenza in the past 6 months preceding enrollment to the trial&#xD;
&#xD;
          -  Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to&#xD;
             postpone receipt of such vaccines until after the Day 28 visit.&#xD;
&#xD;
          -  History of bronchial asthma, chronic lung diseases, chronic rhinitis&#xD;
&#xD;
          -  History of immunodeficiency state&#xD;
&#xD;
          -  History of immunosuppression &lt; 6 months prior to immunization&#xD;
&#xD;
          -  History of anaphylactic or other allergic reactions to influenza vaccine or any&#xD;
             vaccine component or excipient (e.g. egg proteins, gentamicin or thimerosal)&#xD;
&#xD;
          -  History of Guillain-Barré Syndrome or cerebrovascular events&#xD;
&#xD;
          -  Having acute infection with fever &gt; 38 degree Celsius or noninfectious diseases&#xD;
             (within 72 hours) preceding enrollment in the trial&#xD;
&#xD;
          -  Volunteers who have been taking immunoglobulin products or have had a blood&#xD;
             transfusion during past 3 months before the beginning of the trial or planned receipt&#xD;
             of such products prior to the Day 28 visit.&#xD;
&#xD;
          -  Current alcohol abuse or drug addiction that might interfere with the ability to&#xD;
             comply with trial procedures&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator would pose a health risk to the&#xD;
             subject if enrolled, or could interfere with the evaluation of the vaccine&#xD;
&#xD;
          -  Study site employees who are involved in the protocol and/or may have direct access to&#xD;
             study related area&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Punnee Pitisuttithum</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Punnee Pitisuttithum</last_name>
    <phone>(662) 6435599</phone>
    <email>punnee.pit@mahidol.ac.th</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Punnee Pitisuttithum</last_name>
      <phone>6626435599</phone>
      <email>punnee.pit@mahidol.ac.th</email>
    </contact>
    <investigator>
      <last_name>Punnee Pitisuttithum</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Punnee Pitisuttithum</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Influenza Vaccine</keyword>
  <keyword>Tri Fluvac vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

